Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pacific Biosciences (PACB)
NASDAQ:PACB
RESEARCH TOOLSreports
Holding PACB?
Track your performance easily
Earnings Data
Report Date
Feb 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.19Last Year’s EPS
-0.31Same Quarter Last Year
Moderate Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 01, 2018
|% Change Since: -33.06%
|Next Earnings Date:Aug 02, 2018
Earnings Call Sentiment|Neutral
The earnings call presented both positive and negative aspects. While new product launches and strategic financial maneuvers signal future growth potential, current revenue declines and challenging market conditions present immediate concerns.Company Guidance
During the PACB Q3 2024 earnings call, several key metrics and guidance details were discussed. The company reported total revenue of $40 million, reflecting an 11% sequential increase from Q2 2024. This includes 22 Revio systems and five Sequel IIe systems delivered in the quarter. Consumable revenue hit $18.5 million, marking a 10% year-over-year growth, with an annualized pull-through on the Revio platform at approximately $255,000. Despite a difficult macroenvironment, PACB remains committed to achieving cash flow positivity by the end of 2026. The company expects Q4 revenue to be flat to slightly up compared to Q3 2024, with full-year revenue now forecasted to be below the previous estimate of approximately $170 million. Additionally, PACB announced a note exchange with SoftBank to reduce its debt by $259 million, extending the maturity date to August 2029, while balancing shareholder dilution.New Product Launches
PacBio unveiled several new products including the SPRQ chemistry for Revio, which increases data output by 33% and lowers DNA input requirements, and the Vega benchtop sequencer priced at $169,000.
Revenue and Growth
Total revenue for Q3 2024 was $40 million, up 11% sequentially from Q2 2024, with growth in instrument, consumable, and service revenue.
Increased Adoption and Customer Base
Revio system placements continued strong with approximately 45% delivered to new customers year-to-date. There was a record quarter for the Onso system with the most systems shipped since its launch.
Debt Reduction and Financial Flexibility
An agreement with SoftBank to exchange $459 million in notes for $200 million in new notes, 20.5 million shares, and $50 million cash, reducing total notes by $259 million.
---
PACB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PACB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $2.45 | $2.30 | -6.12% |
| Aug 07, 2024 | $1.53 | $1.67 | +9.15% |
| May 09, 2024 | $1.72 | $1.77 | +2.91% |
| Feb 15, 2024 | $6.67 | $5.74 | -13.94% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Pacific Biosciences (PACB) report earnings?
Pacific Biosciences (PACB) is schdueled to report earning on Feb 13, 2025, TBA Not Confirmed.
What is Pacific Biosciences (PACB) earnings time?
Pacific Biosciences (PACB) earnings time is at Feb 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PACB EPS forecast?
PACB EPS forecast for the fiscal quarter 2024 (Q4) is -0.19.
---